Renaissance Capital logo

AKRO News

US IPO Week Ahead: Just 1 biotech is on the calendar in a slow week for the IPO market

ETNB

After a busy week in the IPO market, just one biotech is scheduled to go public in the week ahead. NASH biotech 89bio (ETNB) plans to raise $85 million at a $225 million market cap. The company’s target indication represents a multi-billion-dollar market with no FDA-approved therapy; consequently, there are ...read more

NASHville: 89bio is the latest biotech IPO targeting liver disease NASH

ETNB

Backed by OrbiMed and Longitude, Phase 1 biotech 89bio (ETNB) is expected to raise $70 million tonight in the fifth NASH-focused biotech IPO of 2019; insiders have indicated on $40 million (57% of the deal). Another NASH biotech, Cirius Therapeutics (CSTX), is in the IPO pipeline, but before this year, the last biotech IPO targeting NASH came in...read more

June's flood of biotech IPOs continues with these 4 deals

BBIO

June is seeing a wave of biotech IPOs. Five priced last week, and four more are on the IPO calendar for this week.   Recent biotech IPOs have mostly underperformed, though 2 are up +100% ...read more

US IPO Weekly Recap: WORK's direct listing works as Slack and 6 others go public

WORK

Slack's (WORK) widely-covered direct listing was hailed as a success. Slack opened on Thursday at $38.50, well above the NYSE's "reference price" of $26, and more than triple its last round less than a year ago. And yet, new public investors ended the week with losses. The stock closed Friday at $37.22, down 3.3% from the opening trade. With millions of users...read more